Published January 11th, 2007
Washington, Jan 11 : In the longest ever trial conducted for renal cell carcinoma (RCC), or kidney cancer, the drug Nexavar (sorafenib), has been found to double the average progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC), or kidney cancer.
Related Articles
Nexava reduces death risks among patients with kidney cancer by a quarter
Chinese Ginseng may reduce cancer fatigue
Double gene therapy drastically reduces lung cancer cells in mice
Posted: 01|11|07 at 3:40 pm.
Filed under: News.
Published January 11th, 2007
Washington, Jan 11: In the longest ever trial conducted for renal cell carcinoma (RCC), or kidney cancer, the drug Nexavar (sorafenib), has been found to double the average progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC), or kidney cancer.
Related Articles
Nexava reduces death risks among patients with kidney cancer by a quarter
Chinese Ginseng may reduce cancer fatigue
Double gene therapy drastically reduces lung cancer cells in mice
Posted: 01|11|07 at 10:22 am.
Filed under: News.
